Author: admin

Graphic Stylus Becomes Merchbygs: Rebranding Reflects Growth and Custom Merch Focus

Graphic Stylus is liked for branding and unique artwork. We are happy to announce that it’s now Merchbygs. It now has an updated domain name, merchbygs.com. We support this adjustment to better connect with the company’s changing strategy. We are expanding the focus on unique and excellent customized items. It is for both individuals and businesses.

Why the Rebrand?

The rebrand is a direct result of the brand’s growth journey. What began as a modest graphic design studio has evolved into a full-fledged merchandise company. It also includes a printing solutions hub.

Graphic Stylus initially focused on visual storytelling through design. Now, as the market changed, so did customer needs. Our team starts handling designs and production of customized items. These products include gift sets, hoodies, cups, T-shirts, and more. Now people’s needs are beyond design and logos. They want ready-made and customized goods with unique logos and designs.

Merchbygs, the new identity, welcomes this change.

What’s New – Name, Domain & Direction

Our rebranding includes a targeted and integrated product expansion. The following points show what is new in our business.

● New Brand Name – Merchbygs (short for Merch by GS)

● New Website –https://merchbygs.com

● Expanded Offerings –

1. T-shirts

2. Hoodies

3. Mugs

4. Custom gifting solutions

5. Corporate branding kits

Our focus now shifts from design services to a merchandise-first brand under the new name. Each business can benefit from our tailored solutions, whether it’s through promotional products or custom brand merchandise. It could be a business aiming to leave a lasting impression or a creator looking to launch their own line—Merchbygs is here to help.

Quote from the Founder

“Rebranding as Merchbygs marks a new era for us,” said Malik M. Hemani, Founder of Merchbygs. “We’ve grown beyond graphics into a vibrant space where creativity meets commerce, and our new identity reflects that. It’s not just a new name, it’s a promise to deliver innovative merchandise that works hard for our clients.”

Customer Assurance – What Remains Unchanged

This change gives new opportunities to our loyal clients of Graphic Stylus. We will not lose our old values. The team behind Merchbygs remains the same. They are skilled, committed, and client-focused. Here is what stays consistent:

● Creative Excellence – We focus on strong design thinking in every product.

● Premium quality materials – We provide durable materials and print quality.

● Reliable Delivery – We offer quick turnarounds with dependable timelines.

● Personal Support – We are always available for dedicated guidance from concept to shipment.

Clients can expect the same dependable service and seamless transition to the new platform.

Looking Ahead – Future Plans

Merchbygs is not stopping here. The brand is working on the following points:

● Corporate gifting and B2B merch kits for members.

● Brand launches and events.

● Eco-conscious printing and packaging solutions.

● An interactive online merch design studio. It will allow customers to create and preview their designs in real-time.

● Collaborations with artists and influencers to produce new goods.

Merchbygs wants to build a cooperative ecosystem by offering innovative, eco-friendly promotional products . Our staff will stay ahead of trends and pay close attention to its audience to ensure meaningful and sustainable brand experiences.

Call to Action

Find out what’s new. See what comes next. Go to the new look at new styles. You can begin your brand journey with us. Also, you can look for personalized gift options. We manage both single pieces and big orders. The goal of Merchbygs is to make your ideas memorable, wearable, and shareable.

About Merchbygs

Merchbygs, formerly known as Graphic Stylus , is a custom merchandise brand. It brings together thoughtful design and quality printing. Our offerings range from corporate branding kits to clothing and accessories. Our company helps creators, entrepreneurs, and organizations showcase their identity through personalized merch. Merchbygs is where design meets delivery. It covers ideas to execution.

Media Contact
Company Name: Merchbygs
Email: Send Email
Phone: (866) 978-9587
City: Houston
State: Texas
Country: United States
Website: https://graphicstylus.net/

Science Author Eric Jimenez Unveils His New Book, ‘The Science Behind Respect: Respect is the Fabric of Existence! Volume #1’

With an overarching mission to plant a seed of goodness into today’s generation, Eric Jimenez dives into the scientific underpinnings of respect and its position in existence

Eric Jimenez is breaking ground and bridging the gap between respect and its scientific position in existence with the release of his all-new and highly anticipated book, ‘The Science Behind Respect: Respect is the Fabric of Existence! Volume #1.’

Jimenez is a science writer who is focused on benefiting the environment and future generations by cultivating quality research in his works today. In his personal and professional worlds, Jimenez seeks balance in all things, and his new work displays this by balancing science with humanity. ‘The Science Behind Respect: Respect is the Fabric of Existence! Volume #1’ delves into the science of respect, down to its microscopic and cosmic scales. Everything in the universe is governed by harmonious interactions such as symbiosis and mutualism, all of which demand respect at their core. “Respect and balance are what create equilibrium, a core state required of everything in the universe,” said Jimenez.

Within the pages of his new book, Jimenez sheds light on a captivating new philosophy grounded in science. Readers are taken on a journey that explains the vital role that respect plays in everything from biological beings to world economies. By the time they have finished the book, anyone who reads ‘The Science Behind Respect: Respect is the Fabric of Existence! Volume #1’ will be left with a life-changing new perspective on the world and the universe.

Respect sparks appreciation and sustainability, which are core pillars to the philosophy that Jimenez imparts in ‘The Science Behind Respect: Respect is the Fabric of Existence! Volume #1.’ This groundbreaking new book is ideal for anyone passionate about science, philosophy, ethics, humanity, and everything in between. Boardroom executives and high school students alike can broaden their world-view by simply reading this new book.

‘The Science Behind Respect: Respect is the Fabric of Existence! Volume #1’ is available now on Amazon. Learn more by visiting https://thesciencebehindrespect.com/.

ABOUT ERIC JIMENEZ

Eric Jimenez is a science writer and author of ‘The Science Behind Respect: Respect is the Fabric of Existence! Volume #1’ aiming to make lasting, positive change for the environment and future generations by focusing on sustainability.

Media Contact
Contact Person: Eric Jimenez
Email: Send Email
Phone: 561-503-9974
Country: United States
Website: https://thesciencebehindrespect.com/

Ayahuasca Ceremony in the Amazon: A Deep Dive into the Sacred Ritual

What Is an Ayahuasca Ceremony?

An Ayahuasca ceremony is more than just a ritual – it represents a sacred journey inward. Originating from the Amazon rainforest, this powerful plant medicine has been used for centuries by indigenous communities for emotional and spiritual healing.

For many, it becomes one of the most transformative experiences of their lives. Under the guidance of experienced shamans, participants are invited to explore their subconscious, release emotional burdens, confront fears, and reconnect with their true essence.

This article provides a look into how the Ayahuasca ceremony is conducted at a retreat center in Ecuador and the kinds of inner transformation it often facilitates.

How the Ceremony Is Conducted

Ceremonies are held in a maloca – a large circular ceremonial hut located in the heart of the jungle. Each ceremony begins with a traditional energy cleansing ritual performed by a shaman.

Typically starting around 8:00 PM – a time believed to align with the energetic peak of Ayahuasca – participants lie on individual mattresses arranged in a circle, each equipped with a blanket, pillow, and a bucket for potential physical release. Nearby restrooms are available for comfort.

Groups are kept small, with a maximum of 8 participants per ceremony, ensuring a safe and personalized experience. Each ceremony is guided by an experienced shaman and supported by two assistants who remain present throughout the night.

The shaman blesses the brew with sacred songs (icaros) and flute music before serving it to each participant individually. The space is dimly lit with a single candle, allowing participants to focus inward. Effects typically begin within 30 to 60 minutes, although this can vary.

Inner Experiences During the Ceremony

Each participant’s experience is unique. Some may feel powerful emotions, receive visions, or experience deep personal insights. Others may have a quieter or gentler journey. In some cases, the first ceremony may feel subtle, often due to factors such as diet, intention, or the individual’s sensitivity to the medicine.

Profound realizations and shifts often continue unfolding in the days following the ceremony. Participants frequently report a greater sense of clarity, peace, and emotional resilience. It is not uncommon for life after the ceremony to present new challenges or choices – almost as if the ceremony is still ongoing – offering continued opportunities for growth and transformation.

The Importance of Integration and a Safe Setting

Ayahuasca is considered a sacred plant and must be approached with respect and care. A safe, grounded setting with knowledgeable shamans is essential. Unfortunately, there have been increasing reports of unsafe practices in areas where commercial tourism compromises safety and tradition.

For this reason, many recommend choosing a retreat located within the Amazon rainforest – Ayahuasca’s place of origin – where the surrounding energy of nature powerfully supports the healing process.

For Those Who Feel Called to Experience Ayahuasca

Those feeling called to work with Ayahuasca often seek out safe, respectful, and authentic settings in which to do so. Retreat centers such as Amayas Retreat Center in Ecuador offer this kind of environment. With dedicated shamans and carefully held ceremonial space, participants are supported in opening their hearts, facing their truth, and stepping into powerful transformation.

Learn More:

– What is Ayahuasca – Full Information

– 11-Day Transformational Retreat Program

– Ayahuasca Retreat in Ecuador

Media Contact
Company Name: Amayas Ecuador
Contact Person: Karolína Urbanova
Email: Send Email
Country: Ecuador
Website: https://amayas-ecuador.com

Dr. Edward Lubin Announces Nationwide Opportunity for Future Medical Leaders Through Newly Launched Scholarship Initiative

Dr. Edward Lubin Announces Nationwide Opportunity for Future Medical Leaders Through Newly Launched Scholarship Initiative

Dr. Edward Lubin
Dr. Edward Lubin

Tampa, FL – Dr. Edward Lubin, a respected figure in the field of interventional pain medicine, is proud to introduce the Dr. Edward Lubin Scholarship for Medical Students, a national academic opportunity designed to identify and support the next generation of healthcare professionals. Open to undergraduate students across the United States, this scholarship aims to recognize students who are committed to improving healthcare through innovation, compassion, and a deep sense of purpose.

Hosted through the official scholarship website at https://dredwardlubinscholarship.com, the program invites applicants to submit a brief yet meaningful essay that reflects their personal aspirations in medicine and how they plan to contribute to the evolving landscape of healthcare.

This annual initiative is founded and overseen by Dr. Edward Lubin, a physician whose career has spanned neuroscience research, surgical training, and pain medicine. Through his own academic and clinical journey, Dr. Edward Lubin has come to understand that true change in medicine begins not only with knowledge and skill, but with vision and dedication. The scholarship reflects this belief by offering students a platform to share their goals and values, while also receiving recognition for their dedication to the future of healthcare.

Eligibility Criteria

To qualify, applicants must currently be enrolled as undergraduate students in the United States and must demonstrate a clear interest in pursuing a career in medicine or a related healthcare field. Central to the application process is the submission of an original essay in response to the following prompt:

In 500 words or less, describe how you hope to use your medical education to make a meaningful impact on the future of healthcare. What personal experiences or goals drive your passion for medicine, and how do you envision your role in improving the lives of others?

The deadline to apply for the Dr. Edward Lubin Scholarship for Medical Students is April 15, 2026, with the selected recipient to be announced on May 15, 2026.

Dr. Edward Lubin created this scholarship not just as a financial award but as a meaningful opportunity to uplift those who show an early commitment to service and scientific inquiry. His belief in building a foundation for future physicians is rooted in his own experiences in both academic and clinical settings. The scholarship also reflects Dr. Edward Lubin’s long-standing commitment to patient advocacy and medical education.

With a vision to cultivate leadership in medicine, Dr. Edward Lubin invites students to bring forth their stories, goals, and inspirations—allowing their voices to be heard as part of a broader movement toward a more compassionate and effective healthcare system.

This scholarship is not bound by geographic location and is open to undergraduate applicants from all regions across the United States.

For full details, eligibility requirements, and essay submission guidelines, please visit the official website: https://dredwardlubinscholarship.com.

Media Contact
Company Name: Dr. Edward Lubin Scholarship for Medical Students
Contact Person: Dr. Edward Lubin
Email: Send Email
City: Tampa
State: Florida
Country: United States
Website: https://dredwardlubinscholarship.com

Exoskeleton Market worth $2.03 Billion by 2030, at a CAGR of 29.4%

“Exoskeleton Market”
The global Exoskeleton Market Value is projected to be USD 2.03 billion by 2030, growing from USD 0.56 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 29.4% during the forecast period.

The report “Exoskeleton Market by Component (Sensors, Actuators, Power Systems, Controllers, Software), Functionality (Assistive, Rehabilitative, Augmentative, Preventive), Type (Powered, Passive, Hybrid), Body Part (Lower, Upper, Full Body) – Global Forecast to 2030” The global exoskeleton market is projected to grow from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, at a CAGR of 29.4% during the forecast period. Exoskeletons are wearable robotic systems designed to enhance human capabilities by supporting mobility, reducing fatigue, and aiding rehabilitation. The overall growth of the exoskeleton market is driven by advancements in artificial intelligence and machine learning, which are enabling smarter, more responsive systems that adapt to individual user needs. Key developments such as the FDA clearance of medical exoskeletons are boosting confidence among healthcare providers and expanding clinical adoption.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40697797

Browse 234 market data Tables and 56 Figures spread through 254 Pages and in-depth TOC on “Exoskeleton Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/exoskeleton-market-40697797.html

By mobility, mobile segment to lead market share during forecast period.

The mobile segment is expected to lead the market share during the forecast period due to the wide applicability of mobile exoskeletons across healthcare, industrial, and defense sectors. Unlike stationary systems, mobile exoskeletons are not restricted to clinical settings and enable users to walk, lift, and perform complex movements in real-world conditions. These systems support dynamic movement, allowing users to perform real-world tasks such as walking, lifting, and rehabilitation outside of clinical environments. Their growing use in injury prevention, workforce ergonomics, and personal mobility, combined with significant investments and technological advancements, further drives demand.

By body part, lower extremities segment to dominate market during forecast period.

The lower extremities segment is estimated to hold a prominent position in the Exoskeleton Industry, driven by the increasing demand for mobility solutions among individuals with spinal cord injuries (SCI), stroke, and lower limb disabilities. According to the World Health Organization, over 15 million people globally are living with spinal cord injuries, highlighting the substantial need for assistive mobility technologies. In the US alone, the National Institutes of Health reports approximately 18,000 new cases of SCI annually, with an estimated 255,000 to 390,000 individuals currently living with such conditions. This growing patient base has created a favorable environment for the adoption of lower extremity exoskeletons that enable improved mobility, independence, and rehabilitation outcomes.

North America to lead market during forecast period.

The US holds a dominant position in the North American exoskeleton market due to strong investments, increasing demand across sectors, and advancements in wearable robotic technologies. The country’s leadership is supported by a well-developed healthcare system, a large industrial workforce, and significant military needs. In August 2024, Ekso Bionics Holdings, Inc., a US-based company specializing in exoskeletons for medical and industrial use, announced the pricing of an underwritten public offering of 6 million units. This offer raised approximately USD 6.0 million, highlighting continued investor interest in the sector.

Key Players

The Exoskeleton Companies includes significant Tier I and II players like Ekso Bionics (US), Ottobock (Germany), DIH Medical (Switzerland), Comau (Italy), Myomo Inc. (US), CYBERDYNE Inc. (Japan), Lifeward Ltd. (Israel), Hyundai Motor Group Robotics LAB (South Korea), B-Temia (Canada), Rex Bionics Ltd. (New Zealand), ABLE Human Motion (Spain), Laevo Exoskeletons (Netherlands), German Bionic Systems GmbH (Germany), Levitate Technologies, Inc. (US), and others.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Delray Beach
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/exoskeleton-market-40697797.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exoskeleton Market worth $2.03 Billion by 2030, at a CAGR of 29.4%

Dry Transformer Insulation Market 2025: Business Strategies for Excellent Growth, Highest Revenue, Booming Growth Opportunities – 2030

The dry transformer insulation market is driven by growing demand for safe, efficient, and eco-friendly power solutions. Leading companies like 3M, Sherwin-Williams, and PPG Industries are advancing innovative coatings and materials that enhance performance, durability, and thermal resistance—ensuring reliable operation in critical energy infrastructure worldwide.

The dry transformer insulation market is predicted to reach USD 1.21 billion by 2030 from USD 0.93 billion in 2025, registering a CAGR of 5.5% during the forecast period. The report includes information on market trends and development, dry transformer insulation market growth drivers, emerging technologies, and the investment structure of the market. The growth of the dry transformer insulation market is primarily driven by a high emphasis on safety, sustainability, and technological advancements. The increasing demand for enhanced safety and eco-friendly solutions in power distribution systems serves as a significant catalyst for market expansion. Unlike traditional oil-filled transformers, dry-type transformers employ solid insulation materials, effectively mitigating risks associated with oil leaks and eliminating fire hazards inherent to oil-based units. This characteristic makes them particularly suitable for installations in buildings and urban environments where safety and occupant accessibility are critical.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138692550

Moreover, stringent environmental regulations and rising energy efficiency demands compel power utilities and various industries to transition to cleaner technologies. Dry transformer insulation, which utilizes non-toxic and recyclable materials, reduces overall carbon emissions while supporting green building certifications and sustainability initiatives. The growing adoption of automatic distribution systems, such as smart grids, along with the integration of renewable energy sources, necessitates reliable, low-maintenance, and performance-driven transformers that align with dry insulation technology. Furthermore, the expansion of urban populations and infrastructure development in emerging economies is driving new installations across utilities, real estate, healthcare, and data center sectors, where safety and operational efficiency—both in terms of space and performance—are of utmost importance. As advancements continue to enhance the thermal and mechanical properties of dry insulation systems, their appeal as a viable alternative in the energy sector is poised to increase.

Solid insulation segment to hold largest share of dry transformer insulation market during forecast period

Solid insulation is expected to hold the largest share of the dry transformer insulation market, attributed to its superior performance and safety advantages. Materials such as epoxy resin and polyester exhibit exceptional dielectric strength, thermal stability, and moisture resistance, making solid insulation highly suitable for urban and industrial dry-type applications. Unlike liquid insulation, solid insulation eliminates leakage risks and mitigates fire hazards and environmental contamination, enabling manufacturers to comply with stringent regulations while adhering to sustainability standards.

Furthermore, solid insulation enhances the longevity of transformers by minimizing maintenance requirements and operational costs. The growing demand for safe, reliable, and energy-efficient power distribution systems, particularly in high-density areas and in conjunction with renewable energy sources, underscores the significance of solid insulation. The adaptability of solid insulation facilitates compact designs that can be seamlessly integrated into the limited spaces typical of commercial buildings and data centers. Advances in insulation technology, alongside a balance of manufacturing costs and durability—especially in the Asia Pacific region—have solidified the solid insulation segment’s dominance in the dry transformer insulation market.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=138692550

Windings segment to hold largest share of dry transformer insulation market during forecast period

The winding segment is expected to hold the largest market share due to its critical role in transformer functionality. The insulation of windings necessitates the use of specialized materials. Dry transformers employ solid-state insulation solutions, including epoxy resin, fiberglass, and mica, to encase the windings, facilitating electrical separation and heat dissipation without relying on liquid cooling methods. The production of solid and composite materials is generally capital-intensive, attributed to their fire-resistant and environmentally friendly characteristics and the intricate manufacturing processes involved, such as vacuum pressure impregnation and cast resin encapsulation, which significantly enhance durability and safety. The rising demand for energy-efficient and environmentally sustainable transformers—driven by trends such as urbanization, industrialization, and the integration of renewable energy sources—further fuels the need for specialized insulation for windings. These components must endure high voltage conditions and exceptional operational environments, requiring the use of premium, high-cost materials such as coated copper or aluminum conductors. This necessity escalates the overall expenditure and amplifies the market share associated with windings.

Europe to be second-largest market for dry transformer insulation during forecast period

Europe commands the second-largest share of the dry transformer insulation market for several key reasons. Firstly, the region is characterized by robust regulations and a comprehensive decarbonization strategy that emphasizes sustainability and energy efficiency. The European Union (EU) is increasingly implementing policies designed to address environmental challenges and facilitate decarbonization across its member states. This regulatory landscape is driving significant investments and productivity enhancements that align with these sustainability goals.

Dry-type transformers, which utilize solid insulation instead of oil, are well-aligned with these objectives due to their reduced environmental hazards, greater safety, and minimal maintenance requirements. The urgency to modernize aging power infrastructure within Europe necessitates substantial immediate investments to upgrade or replace outdated systems. This modernization is essential for effectively integrating the renewable energy funding required in this transition. Consequently, the development of efficient, safe, and compact transformer solutions is critical.

Additionally, Europe represents one of the most advantageous markets globally for firms with a mature industrial base focused on tangible results. The robust growth of dry-type transformer manufacturers can be attributed to their capacity for innovation and the enhancement of existing engineering capabilities related to materials and insulation. The transformation of energy infrastructure is imperative to accommodate urbanization, resulting in heightened demand for advanced systems, particularly in countries like Germany, France, and the UK that are progressing towards smart grid solutions. Furthermore, the emphasis on minimizing fire risks associated with environmental safety significantly enhances the attractiveness of dry transformers in comparison to traditional oil-filled models.

Dry Transformer Insulation Companies

The dry transformer insulation market report comprises key manufacturers including 3M (US), The Sherwin-Williams Company (US), PPG Industries, Inc. (US), DuPont (US), WEG (Brazil), Huntsman International LLC (US), ALTANA AG (Germany), Krempel GmbH (Germany), PUCARO Electrical Insulation GmbH (Germany), and Kansai Altan (Turkey).

3M (US) is a global leader in science and innovation, offering 60,000+ products across sectors. It focuses on sustainable growth, investing over USD 1.1 billion in R&D in 2024. Its dry-type transformer coatings enhance durability and efficiency, supporting energy and automotive infrastructure globally.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=138692550

Sherwin-Williams (US) provides advanced coatings through its Performance Coatings Group, with strong global manufacturing and distribution. Its transformer coatings offer fire resistance, insulation, and moisture protection, vital for energy systems.

PPG Industries (US) delivers high-performance coatings for industrial use in 70+ countries. Its transformer solutions, including ENVIROCRON and Hi-Temp powder coatings, meet strict thermal and electrical standards. PPG continues expanding production to ensure regional support and quality.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/dry-transformer-insulation-market-138692550.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Transformer Insulation Market 2025: Business Strategies for Excellent Growth, Highest Revenue, Booming Growth Opportunities – 2030

Winners of the 2025 American Consumer Awards “Automotive” Category for Texas Announced by American Consumer Assessment Inc.

The results of the 2025 American Consumer Awards in the ‘Automotive’ category, organized by the American Consumer Right Association and managed by the American Consumer Assessment, have been announced for the Texas region.

These awards aim to uphold consumers’ fundamental rights by sharing results based on consumer evaluations, providing objective and valuable information, and promoting the qualitative enhancement of consumers’ lives.

Evaluations for the 2025 American Consumer Awards ‘Automotive’ category were conducted from March to June, and we conducted an evaluation through review platforms. The evaluation criteria included facility standards, staff service quality, pricing transparency, accessibility and customer responsiveness. A total of 11 businesses received awards in this category.

Auto repair shop :

Ancira Winton Chevrolet

Burleson Nissan

Grapevine Ford Service

Toyota of Pharr

Toyota of Rockwall

Car dealer :

Family Toyota of Arlington

Family Toyota of Burleson

Sterling McCall Lexus

Toyota of Cedar Park

Car repair and maintenance service :

Gullo Ford of Conroe

NuBrakes Mobile Brake Repair (W Point Street)

A spokesperson for the American Consumer Assessment Inc. stated, “The 2025 American Consumer Awards are grounded in evaluations from real consumers, and we hope these results will provide trustworthy information for consumers and contribute to the growth of the Automotive industry. We also believe that these assessments will encourage businesses to prioritize customer satisfaction and continue to offer exceptional service.”

Media Contact
Company Name: American Consumer Assessment Inc.
Contact Person: Harvey Reed
Email: Send Email
City: Los Angeles
State: CA
Country: United States
Website: https://www.usa-aca.com/

Advanced Pain Care Launches Neurology Department for Holistic Pain Management in Austin

Advanced Pain Care provides the most effective, comprehensive treatment for pain. We announced the official launch of our Neurology Department. This strategic expansion aims to provide patients with more specialized care. It is for chronicpain, migraines, nerve disorders, and related neurological conditions.

Integrated Care for ComplexPain Conditions

Chronicpain often overlaps with neurological disorders. We know that the conditions include migraines, neuropathy, and nerve compression cause severe pain. You need an expert neurological understanding to relieve pain. Advanced Pain Care is making good progress in response to this demand. We are incorporating neurologyinto our current services. These services are rheumatology consultations and physical therapy. Our clinic is improving its ability to deliver comprehensive care. Patients in Austin and across Texascan get advanced pain relief services and recovery.

WhatPatients CanExpect

Our newly launched Neurology Department will focus on diagnosis and treatment. It includes conditions such as epilepsy, multiple sclerosis, neuropathy, and post-surgical nerve damage. Our objective is to deal with the underlying causes of pain. We will offer an exact diagnosis and effective treatment.

This addition enhances the other specializations offered by the clinic. The other specializations include physical therapy, interventional treatments, and care provided by a rheumatology doctor. This integration leads to simplified referrals and individualized treatment programs. Patients will experience continuous and quality care, with the entire process—from diagnosis tor ecovery—tailored to their specific needs.

A Vision for HolisticHealing

“Our mission has always been to treat the whole person, not just the pain,” said Dr. Mark T. Malone. He is the founder and Medical Director of Advanced Pain Care. “The addition of neurology strengthens our multidisciplinary approach. It allows patients to access specialized care more efficiently and effectively.”

This action is a continuation of ongoing treatment focused on patients. It balances innovation and expertise. We are encouraging rheumatologists, physical therapists, and neurologists to work together. It will benefit the patients.

Expanding Access Across Austin and Central Texas

We serve around Austin and Central Texas. We also cover areas around Round Rock and Cedar Park. Advanced Pain Care brings high-quality services within the reach of patients. Patients with chronic migraines, nerve-related disorders, or joint inflammation should visit once. Neurology in Austin is easily available to patients. There will be no need for multiple referrals.

This approach not only improves treatment outcomes but also reduces the stress of navigating complex care systems. It is especially for patients living with long-term conditions.

Take theFirst Step TowardRelief

Learn more about the new Neurology Department. Schedule an appointment with a neurologist, rheumatologist, or physical therapy specialist by visiting us online.

Patients in Austin and across Texasnow have more reasons to trust Advanced Pain Care. We will provide complete, compassionate, and coordinated painmanagement.

About AdvancedPain Care

Advanced Pain Care was established in 2002. It is a reputable leader in Texas for pain treatment services. We have a multidisciplinary team including pain specialists near me, surgeons, neurologists,rheumatologists, and physical therapists. Our clinic provides good care for both regular and severe pain. We always focus on continuous innovation and patient-first values. Advanced Pain Care remains committed to improving lives through better pain solutions.

Media Contact
Company Name: Advanced Pain Care
Email: Send Email
Phone: 512-244-4272
Country: United States
Website: https://austinpaindoctor.com/

Dementia Associated With Alzheimer’s Disease Pipeline Appears Promising With 80+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Dementia Associated With Alzheimer’s Disease Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Dementia Associated With Alzheimer’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dementia Associated With Alzheimer’s Disease Research. Learn more about our innovative pipeline today! @ Dementia Associated With Alzheimer’s Disease Pipeline Outlook

Key Takeaways from the Dementia Associated With Alzheimer’s Disease Pipeline Report

  • In July 2025, MapLight Therapeutics announced a Phase 2 study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer’s Disease Psychosis (ADP).
  • In July 2025, Karuna Therapeutics conducted a Phase 3 study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028.
  • DelveInsight’s Dementia Associated With Alzheimer’s Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Dementia Associated With Alzheimer’s Disease treatment.
  • The leading Dementia Associated With Alzheimer’s Disease Companies such as BioVie, Bristol Myers Squibb, Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. and others.
  • Promising Dementia Associated With Alzheimer’s Disease Pipeline Therapies such as ITI-1284, Brexpiprazole, ONO-2020, ML-007C-MA, KarXT, Quetiapine Fumarate, DMB-I (Dimebon), aripiprazole, PYM50028, Crenezumab, and others.

Stay informed about the cutting-edge advancements in Dementia Associated With Alzheimer’s Disease treatments. Download for updates and be a part of the revolution in Central Nervous System care @ Dementia Associated With Alzheimer’s Disease Clinical Trials Assessment

Dementia Associated With Alzheimer’s Disease Emerging Drugs Profile

  • NE3107: BioVie

NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). NFκB is activated by amyloid beta and tau — two proteins that form toxic clumps that contribute to Alzheimer’s — and by the pro-inflammatory molecules that it stimulates, leading to chronic inflammation. NE3107 was found to have no immunosuppressive effects and to block ERK- and NF-κB-induced inflammation without suppressing their functions involved in maintaining overall balance, such as insulin signaling and nerve cell growth and survival. Currently, the drug is in Phase III stage of development for the treatment of Alzheimer Disease.

  • AMX0035: Amylyx Pharmaceuticals Inc

AMX0035 is an investigational, oral, fixed-dose combination of sodium Phenylbutyrate (PB) and Taurursodiol (TURSO). This combination therapy is designed to reduce neuronal death through two mechanisms: sodium phenylbutyrate decreases Endoplasmic Reticulum (ER) stress (by upregulating the master chaperone regulator DJ-1) and TUDCA mitigates mitochondrial dysfunction (by incorporating into the mitochondrial membrane and increasing apoptotic threshold). AMX0035 is designed to slow or mitigate neurodegeneration by targeting endoplasmic reticulum (ER) stress and mitochondrial dysfunction, two connected central pathways that lead to cell death and neurodegeneration. Preclinical studies have provided evidence that AMX0035 may reduce cell death and improve cellular function, also supporting the synergistic effect of AMX0035 compared to individual compounds. Currently, the drug is in the Phase II stage of its development for the treatment of Alzheimer’s disease.

  • CT-1812: Cognition Therapeutics

Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer’s disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer’s-disease.

  • CM383: KeyMed Biosciences

CM383 is an investigational drug being developed for the treatment of Alzheimer’s disease. It is a small molecule designed to target the underlying mechanisms of the disease, specifically by modulating the immune response and reducing neuroinflammation, which are key factors in Alzheimer’s pathology. CM383 works by targeting the immune system’s response to amyloid-beta plaques, which are characteristic of Alzheimer’s disease. It aims to enhance the brain’s ability to clear these plaques and improve neuronal health. This approach is distinct from many traditional Alzheimer’s treatments that primarily focus on amyloid plaque reduction or cholinergic modulation. Currently, the drug is in the Phase I stage of development to treat Alzheimer’s-disease.

The Dementia Associated With Alzheimer’s Disease Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dementia Associated With Alzheimer’s Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dementia Associated With Alzheimer’s Disease Treatment.
  • Dementia Associated With Alzheimer’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dementia Associated With Alzheimer’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dementia Associated With Alzheimer’s Disease market.

Learn more about Dementia Associated With Alzheimer’s Disease Drugs opportunities in our groundbreaking Dementia Associated With Alzheimer’s Disease research and development projects @ Dementia Associated With Alzheimer’s Disease Unmet Needs

Dementia Associated With Alzheimer’s Disease Companies

BioVie, Bristol Myers Squibb, Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. and others.

Dementia Associated With Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Dementia Associated With Alzheimer’s Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Dementia Associated With Alzheimer’s Disease treatment by visiting our website. Stay informed about how we’re transforming the future of Central Nervous System @ Dementia Associated With Alzheimer’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Dementia Associated With Alzheimer’s Disease Pipeline Report

  • Coverage- Global
  • Dementia Associated With Alzheimer’s Disease Companies- BioVie, Bristol Myers Squibb, Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. and others.
  • Dementia Associated With Alzheimer’s Disease Pipeline Therapies- ITI-1284, Brexpiprazole, ONO-2020, ML-007C-MA, KarXT, Quetiapine Fumarate, DMB-I (Dimebon), aripiprazole, PYM50028, Crenezumab, and others.
  • Dementia Associated With Alzheimer’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Dementia Associated With Alzheimer’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dementia Associated With Alzheimer’s Disease Pipeline on our website @ Dementia Associated With Alzheimer’s Disease Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Dementia Associated With Alzheimer’s Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Dementia Associated With Alzheimer’s Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NE3107: BioVie
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CT-1812: Cognition Therapeutics
  12. Early Stage Products (Phase I)
  13. CM383: KeyMed Biosciences
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Dementia Associated With Alzheimer’s Disease Key Companies
  20. Dementia Associated With Alzheimer’s Disease Key Products
  21. Dementia Associated With Alzheimer’s Disease- Unmet Needs
  22. Dementia Associated With Alzheimer’s Disease- Market Drivers and Barriers
  23. Dementia Associated With Alzheimer’s Disease- Future Perspectives and Conclusion
  24. Dementia Associated With Alzheimer’s Disease Analyst Views
  25. Dementia Associated With Alzheimer’s Disease Key Companies
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dementia-associated-with-alzheimers-disease-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dementia Associated With Alzheimer’s Disease Pipeline Appears Promising With 80+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

HER2+ Gastric Cancer Pipeline Appears Promising With 20+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight’s, “HER2 Positive Gastric Cancer Pipeline Insight” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in HER2 Positive Gastric Cancer pipeline landscape. It covers the HER2 Positive Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in HER2 Positive Gastric Cancer Research. Learn more about our innovative pipeline today! @ HER2 Positive Gastric Cancer Pipeline Outlook

Key Takeaways from the HER2 Positive Gastric Cancer Pipeline Report

  • In July 2025, AstraZeneca announced a study is to assess the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.
  • In July 2025, Daiichi Sankyo conducted a clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS
  • DelveInsight’s HER2 Positive Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment.
  • The leading HER2 Positive Gastric Cancer Companies such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
  • Promising HER2 Positive Gastric Cancer Therapies such as YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.

Stay informed about the cutting-edge advancements in HER2 Positive Gastric Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ HER2 Positive Gastric Cancer Clinical Trials Assessment

HER2 Positive Gastric Cancer Emerging Drugs

  • SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.

SHR-A1811 is a novel anti-HER2 antibody-drug conjugate (ADC) that features an optimized molecular design to enhance plasma stability and bystander effect. Hengrui Pharma is currently conducting more than 10 clinical studies of SHR-A1811 from phase 1 to phase 3 to evaluate its safety and efficacy as single agent or combination therapy in a wide variety of cancer indications. Currently, the drug is in Phase III stage of its development for the treatment of HER2-positive Gastric Cancer.

  • Cinrebafusp alfa: Pieris Pharmaceuticals

Cinrebafusp alfa (PRS-343) is a 4-1BB/HER2 fusion protein comprising 4-1BB-targeting Anticalin proteins and a HER2-targeting antibody. The drug candidate is currently in phase 2 development for the treatment of HER2-expressing solid tumors. In phase 1 studies, cinrebafusp alfa has shown an acceptable safety profile at all doses tested with no dose-limiting toxicities. The bispecific also showed a dose response and a 4-1BB-driven mechanism of action based on clinical benefit and pharmacodynamic correlates. Currently, the drug is in Phase II stage of its development for the treatment of HER2-positive Gastric Cancer.

  • BI-1607: BioInvent International

BI-1607 is an FcγRIIB-blocking antibody that differs from BI-1206 (BioInvent’s clinical-stage FcγRIIB antibody) in that it has been engineered for reduced Fc-binding to FcγRs. Preclinical proof-of-concept data indicate that combined treatment with BI-1607 may both enhance efficacy of current anti-HER2 regimens and increase response rates in patients no longer responding to anti-HER2-directed therapies such as trastuzumab. Currently, the drug is in Phase I/II stage of its development for the treatment of HER2-positive Gastric Cancer.

The HER2 Positive Gastric Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Positive Gastric Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Positive Gastric Cancer Treatment.
  • HER2 Positive Gastric Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • HER2 Positive Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Positive Gastric Cancer market.

Learn more about HER2 Positive Gastric Cancer Drugs opportunities in our groundbreaking HER2 Positive Gastric Cancer Research and development projects @ HER2 Positive Gastric Cancer Unmet Needs

HER2 Positive Gastric Cancer Companies

Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.

​​​​​​HER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

HER2 Positive Gastric Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in HER2 Positive Gastric Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ HER2 Positive Gastric Cancer Market Drivers and Barriers, and Future Perspectives

HER2 Positive Gastric Cancer Companies and Therapies

  • BDC-1001: Bolt Therapeutics Inc.
  • KN026: Shanghai JMT-Bio Inc.
  • YH32367: Yuhan Corporation
  • Margetuximab: MacroGenics
  • Zanidatamab: Jazz Pharmaceuticals

Scope of the HER2 Positive Gastric Cancer Pipeline Report

  • Coverage- Global
  • HER2 Positive Gastric Cancer Companies- Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
  • HER2 Positive Gastric Cancer Therapies- YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
  • HER2 Positive Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • HER2 Positive Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of HER2 Positive Gastric Cancer Pipeline on our website @ HER2 Positive Gastric Cancer Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. HER2-positive Gastric Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HER2-positive Gastric Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Cinrebafusp alfa: Pieris Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. BI-1607: BioInvent International
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. HER2-positive Gastric Cancer Key Companies
  21. HER2-positive Gastric Cancer Key Products
  22. HER2-positive Gastric Cancer- Unmet Needs
  23. HER2-positive Gastric Cancer- Market Drivers and Barriers
  24. HER2-positive Gastric Cancer- Future Perspectives and Conclusion
  25. HER2-positive Gastric Cancer Analyst Views
  26. HER2-positive Gastric Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2+ Gastric Cancer Pipeline Appears Promising With 20+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight